Pharmacogenetics and the treatment of HIV-/HCV-coinfected patients.

abstract：:Pharmacogenomics (PGx) implementation in clinical practice is steadily increasing. PGx uses genetic information to personalize medication use, which increases medication efficacy and decreases side effects. The availability of clinical PGx guidelines is essential for its implementation in clinical settings. Currently,...

journal_title：Pharmacogenomics

authors： Nagy M,Attya M,Patrinos GP

更新日期：2020-11-01 00:00:00

abstract：:Choline phospholipid metabolism is altered in a wide variety of cancers. The choline metabolite profile of tumors and cancer cells is characterized by an elevation of phosphocholine and total choline-containing compounds. Noninvasive magnetic resonance spectroscopy can be used to detect this elevation as an endogenous...

journal_title：Pharmacogenomics

authors： Glunde K,Serkova NJ

更新日期：2006-10-01 00:00:00

abstract：:Chronic obstructive pulmonary disease (COPD) is influenced by genetic and environmental factors. A large number of candidate gene-association studies and genome-wide linkage scans have been conducted to elucidate the genetic architecture underlying this disease. The compilation of these studies clearly revealed the co...

journal_title：Pharmacogenomics

authors： Bossé Y

更新日期：2009-04-01 00:00:00

abstract：AIM:The present study introduces a simple method for CYP2D6 genotyping that not only determines the heterozygous or homozygous deletions and duplications, but also distinguishes tandem hybrids. MATERIALS & METHODS:Using two commercially available methods, 49 Korean male subjects were genotyped for CYP2D6. The Affymetr...

journal_title：Pharmacogenomics

authors： Kim J,Lee SY,Lee KA

更新日期：2012-06-01 00:00:00

abstract：:Parkinson's disease (PD) is unique among neurodegenerative disorders because a highly effective pharmacological symptomatic treatment is available. The marked variability in drug response and in adverse profiles associated with this treatment led to the search of genetic markers associated with these features. We pres...

journal_title：Pharmacogenomics

authors： Schumacher-Schuh AF,Rieder CR,Hutz MH

更新日期：2014-06-01 00:00:00

abstract：AIM:Our objective was to describe the association between voriconazole concentrations and CYP2C19 diplotypes in pediatric cancer patients, including children homozygous for the CYP2C19*17 gain-of-function allele. MATERIALS & METHODS:A linear mixed effect model compared voriconazole dose-corrected trough concentrations...

journal_title：Pharmacogenomics

authors： Hicks JK,Crews KR,Flynn P,Haidar CE,Daniels CC,Yang W,Panetta JC,Pei D,Scott JR,Molinelli AR,Broeckel U,Bhojwani D,Evans WE,Relling MV

更新日期：2014-06-01 00:00:00

abstract：AIM:To investigate the pharmacokinetics of voriconazole when administered to HIV-positive patients receiving treatment with atazanavir-containing therapies according to CYP2C19 genotype. MATERIALS & METHODS:We describe four HIV-positive patients with pulmonary aspergillosis treated with voriconazole and atazanavir-bas...

journal_title：Pharmacogenomics

authors： Calcagno A,Baietto L,Pagani N,Simiele M,Audagnotto S,D'Avolio A,De Rosa FG,Di Perri G,Bonora S

更新日期：2014-07-01 00:00:00

abstract：:Cancers of the colon are commonly treated with fluoropyrimidines, which often cause severe toxicities in patients with certain variants in DPYD. Y186C (rs115232898) and a variant in the 3' untranslated region (rs12132152) are uncommon alleles previously observed in African-Americans. An African-American female underwe...

journal_title：Pharmacogenomics

authors： Sissung TM,Cordes L,Peer CJ,Gandhy S,Redman J,Strauss J,Figg WD

更新日期：2021-01-01 00:00:00

abstract：AIM:To determine diagnostic accuracy of HLA-B*57:01 testing for prediction of abacavir-induced hypersensitivity and to quantify the clinical benefit of pretreatment screening through a meta-analytic review of published studies. METHODS:A comprehensive search was performed up to June 2013. The methodological quality of...

journal_title：Pharmacogenomics

authors： Cargnin S,Jommi C,Canonico PL,Genazzani AA,Terrazzino S

更新日期：2014-05-01 00:00:00

abstract：:Pharmacogenomics examines how the benefits and adverse effects of a drug vary among patients in a target population by analyzing genomic profiles of individual patients. Personalized medicine prescribes specific therapeutics that best suit an individual patient. Much current research focuses on developing genomic biom...

journal_title：Pharmacogenomics

authors： Chen JJ,Lin WJ,Chen HC

更新日期：2013-06-01 00:00:00

abstract：:A letter in response to: Andersson ML, Eliasson E, Lindh JD. A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele. Pharmacogenomics 13(7), 757-762 (2012). ...

journal_title：Pharmacogenomics

authors： Botton MR,Hutz MH,Suarez-Kurtz G

更新日期：2012-11-01 00:00:00

abstract：:The etiology of statin intolerance is hypothesized to be due to genetic variants that impact statin disposition and clearance. We sought to determine whether genetic variants were associated to statin intolerance. The studied cohort consisted of hyperlipidemic participants (n = 90) clinically diagnosed with statin int...

journal_title：Pharmacogenomics

authors： V Willrich MA,Kaleta EJ,Bryant SC,Spears GM,Train LJ,Peterson SE,Lennon VA,Kopecky SL,Baudhuin LM

更新日期：2018-01-01 00:00:00

abstract：:Fibromyalgia syndrome (FMS) is a common chronic widespread pain syndrome mainly affecting women. Although the etiology of FMS is not completely understood, varieties of neuroendocrine disturbances, as well as abnormalities of autonomic function, have been implicated in its pathogenesis. The exposure of a genetically p...

journal_title：Pharmacogenomics

authors： Buskila D,Sarzi-Puttini P,Ablin JN

更新日期：2007-01-01 00:00:00

abstract：AIMS:The current study investigates whether or not functional polymorphisms in the ATP-binding cassette transporter gene ABCG2 might affect gefitinib activity and/or toxicity in non-small-cell lung cancer (NSCLC) patients. MATERIALS & METHODS:Towards this end, ABCG2 polymorphisms and expression were assessed in DNA an...

journal_title：Pharmacogenomics

authors： Lemos C,Giovannetti E,Zucali PA,Assaraf YG,Scheffer GL,van der Straaten T,D'Incecco A,Falcone A,Guchelaar HJ,Danesi R,Santoro A,Giaccone G,Tibaldi C,Peters GJ

更新日期：2011-02-01 00:00:00

abstract：:Vitamin K antagonists (coumarins) are widely-used oral anticoagulants for the prevention of venous thromboembolism and strokes. Wide inter-individual variation in dose response and frequent bleeds characterize the initiation of coumarin therapy. Over the past 10 years both genetic and nongenetic determinants of coumar...

journal_title：Pharmacogenomics

authors： Voora D,McLeod HL,Eby C,Gage BF

更新日期：2005-07-01 00:00:00

abstract：:The advent of genome-wide association studies has allowed considerable progress in the identification and robust replication of common gene variants that confer susceptibility to common diseases and other phenotypes of interest. These genetic effect sizes are almost invariably moderate to small in magnitude and single...

journal_title：Pharmacogenomics

authors： Zeggini E,Ioannidis JP

更新日期：2009-02-01 00:00:00

abstract：:High-throughput data collection using gene microarrays has great potential as a method for addressing the pharmacogenomics of complex biological systems. Similarly, mechanism-based pharmacokinetic/pharmacodynamic modeling provides a tool for formulating quantitative testable hypotheses concerning the responses of comp...

journal_title：Pharmacogenomics

authors： Almon RR,DuBois DC,Piel WH,Jusko WJ

更新日期：2004-07-01 00:00:00

abstract：:In vitro human cell line models have been widely used for cancer pharmacogenomic studies to predict clinical response, to help generate pharmacogenomic hypothesis for further testing, and to help identify novel mechanisms associated with variation in drug response. Among cell line model systems, immortalized cell line...

journal_title：Pharmacogenomics

authors： Niu N,Wang L

更新日期：2015-01-01 00:00:00

abstract：:Evaluation of: Woynarowski JM, Krugliak M, Ginsburg H: Pharmacogenomic analyses of targeting the AT-rich malaria parasite genome with AT-specific alkylating drugs. Mol. Biochem. Parasitol. 154(1), 70-81 (2007) [1] . The sequencing of the malaria genome sought to expose the parasite's ability to cause disease and ident...

journal_title：Pharmacogenomics

authors： Yanow SK,Purcell LA,Lee M,Spithill TW

更新日期：2007-09-01 00:00:00

abstract：:Drug-induced liver injury (DILI) is an increasing health problem and a challenge for physicians, regulatory bodies and the pharmaceutical industry, not only because of its potential severity and elusive pathogenesis but also because it is often inaccurately diagnosed, commonly missed entirely and more often not report...

journal_title：Pharmacogenomics

authors： Andrade RJ,Robles M,Ulzurrun E,Lucena MI

更新日期：2009-09-01 00:00:00

abstract：:High rates of mortality due to both suicide and medical comorbidities in bipolar patients can be decreased through the administration of lithium, which affects the cerebral endothelium as well as neurons. To investigate the role of ADCY2 in risk of bipolar disorder, we genotyped the ADCY2 rs2290910 in bipolar patients...

journal_title：Pharmacogenomics

authors： Aghabozorg Afjeh SS,Shams J,Hamednia S,Boshehri B,Olfat A,Omrani MD

更新日期：2020-09-01 00:00:00

abstract：:Quantitative trait analysis (QTA) can be used to test whether the expression of a particular gene significantly correlates with some ordinal variable. To limit the number of false discoveries in the gene list, a multivariate permutation test can also be performed. The purpose of this study is to identify peripheral bl...

journal_title：Pharmacogenomics

authors： Whistler T,Taylor R,Craddock RC,Broderick G,Klimas N,Unger ER

更新日期：2006-04-01 00:00:00

abstract：:Randomized controlled trials are the gold standard for determining the efficacy of therapeutic interventions. However, medical practice has not evolved around the concept of randomized trials, but around the idea of careful observations, (anecdotal) case studies and the evaluation of retrospective data. Interventions ...

journal_title：Pharmacogenomics

authors： Frueh FW

更新日期：2009-07-01 00:00:00

abstract：:Currently, there is sufficient evidence for the use of pharmacogenetic information to optimize medication prescribing, but why has this information not been integrated into the drug prescribing process to improve patient care? A discussion about the major contributing factors that have limited the use of pharmacogenet...

journal_title：Pharmacogenomics

authors： Wiltshire T,Dong OM

更新日期：2018-04-01 00:00:00

abstract：:COVID-19 utilizes the ACE2 pathway as a means of infection. Early data on COVID-19 suggest heterogeneity in the severity of symptoms during transmission and infection ranging from no symptoms to death. The source of this heterogeneity is likely multifaceted and may have a genetic component. Demographic and clinical co...

journal_title：Pharmacogenomics

authors： Snyder EM,Johnson BD

更新日期：2020-07-01 00:00:00

abstract：:Incidental findings have long posed challenges for healthcare providers, but the scope and scale of these challenges have increased with the introduction of new technologies. This article assesses the impact of incidental findings on the introduction of prospective pharmacogenomic testing into clinical use. Focusing o...

journal_title：Pharmacogenomics

authors： Brothers KB,Langanke M,Erdmann P

更新日期：2013-08-01 00:00:00

abstract：:The narrow therapeutic range and wide interpatient variability in dose requirement make anticoagulation response to coumarin derivatives unpredictable. As a result, patients require frequent monitoring to avert adverse effects and maintain therapeutic efficacy. Polymorphisms in VKORC1 and CYP2C9 jointly account for ab...

journal_title：Pharmacogenomics

authors： van Schie RM,Wadelius MI,Kamali F,Daly AK,Manolopoulos VG,de Boer A,Barallon R,Verhoef TI,Kirchheiner J,Haschke-Becher E,Briz M,Rosendaal FR,Redekop WK,Pirmohamed M,Maitland van der Zee AH

更新日期：2009-10-01 00:00:00

abstract：AIM:A population pharmacokinetic (PPK) analysis was conducted to describe the influence of GSTA1 polymorphisms on intravenous busulfan in adults undergoing allogeneic hematopoietic stem cell transplantation. PATIENTS & METHODS:A PPK model was developed from 36 patients by a one-compartment model with first-order elimi...

journal_title：Pharmacogenomics

authors： Choi B,Kim MG,Han N,Kim T,Ji E,Park S,Kim IW,Oh JM

更新日期：2015-01-01 00:00:00

abstract：AIM:To find new genetic loci associated with statin response, and to investigate the association of a genetic risk score (GRS) with this outcome. PATIENTS & METHODS:In a discovery meta-analysis (five studies, 1991 individuals), we investigated the effects of approximately 50000 single nucleotide polymorphisms on stati...

journal_title：Pharmacogenomics

authors： Leusink M,Maitland-van der Zee AH,Ding B,Drenos F,van Iperen EP,Warren HR,Caulfield MJ,Cupples LA,Cushman M,Hingorani AD,Hoogeveen RC,Hovingh GK,Kumari M,Lange LA,Munroe PB,Nyberg F,Schreiner PJ,Sivapalaratnam S,de Ba

更新日期：2016-04-01 00:00:00

abstract：:Abacavir is an effective antiretroviral drug used to treat HIV-1 infection. Approximately 5% of patients treated with abacavir develop a hypersensitivity reaction that requires discontinuation of the drug. In an initial pharmacogenetic study conducted in a predominantly White male population, multiple markers in the h...

journal_title：Pharmacogenomics

authors： Hughes AR,Mosteller M,Bansal AT,Davies K,Haneline SA,Lai EH,Nangle K,Scott T,Spreen WR,Warren LL,Roses AD,CNA30027 Study Team.,CNA30032 Study Team.

更新日期：2004-03-01 00:00:00